RAPID: Collaborative Research: One-step Express Test for Presymptomatic Detection to Prevent COVID-19 Spread

RAPID：协作研究：症状前检测的一步快速测试以防止 COVID-19 传播

• 批准号: 2032582
• 负责人: Slava Rotkin
• 金额: $ 16.4万
• 依托单位: Pennsylvania State Univ University Park
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-01 至 2022-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2032582&HistoricalAwards=false
• 关键词: RAPID; Collaborative; Research; step; Express

The fast and untamed outbreak of severe acute respiratory syndrome coronavirus (SARS-CoV-2) is an unprecedented public health emergency that requires immediate attention to reduce morbidity and mortality. During the novel corona virus (COVID-19) outbreak, it appears that thousands of potentially infected individuals showing no apparent symptoms have played a role in propagating a global pandemic disease, with a high infection level in US. Addressing this issue requires development of new technologies for testing for the virus. Importantly, it is crucial to have available simple, reliable, and cost-effective methods for early detection of the virus in large numbers of infected individuals, including those who have no apparent symptoms. Furthermore, such new methods are anticipated to allow for assessment of a high volume of test samples under disease outbreak conditions and be key to understanding immunity levels. With this award, the Chemical Measurement and Imaging Program in the Division of Chemistry is supporting the research of Drs. Slava V. Rotkin, Daniel J. Hayes, Suresh V. Kuchipudi (The Pennsylvania State University, PSU), and Dr. Tetyana Ignatova (University of North Carolina at Greensboro, UNCG) and their collaborators to develop a novel, accurate, and inexpensive prescreening test that takes on the grand challenge of sensing small numbers of live virus particles. The new sensing route addresses important concerns about virus detection at early stages of the disease and less-than-obvious test results from other methods, which have limited the creation of a clear epidemiologic picture. This project investigates a new chemical approach that allows one to "see" concentrated live virus particles by using a combination of magnetic forces applied to nanoparticles bound to the outside of the virus and forces between the virus and its surroundings during creation of miniature liquid drops, all taking place inside a 3-D printed sensor device. The new sensor has great potential to deliver rapid, easy, and at the site of need, information about virus presence, as well as its role regarding mechanisms of viral shedding and preventing the spread of the disease. This technology is envisioned to be useful in detection of other important virus-based diseases, both in humans and animals.The project aims at the development of a new technology for a personal care express viral test – responding but not limited to, COVID-19. Specifically, the project is directed at enabling detection of a viral dose of less than 1,000 virus particles, which corresponds to a typical level in respiratory specimens of an infected individual well in advance of when severe symptoms can be perceived. Achieving such a low limit of detection for non-nucleic acid-based methods is a challenging task, due to fundamental limits for chemical reaction with an analyte. In this project, additional concentration of analyte is approached by combining selective binding of fluorescently tagged magnetic nanoparticles to the glycoprotein of the SARS-CoV-2 corona, followed by aqueous two-phase separation. The project is directed at answering a number of fundamental questions regarding: recognition of live viruses via functionalization of the virus surface with angiotensin converting enzyme 2 labeled staining tag and nanoparticles; chemical and physical processes of acceleration of such a "sandwich" assembly in the micro-volume of transient droplets in the emulsion; and chemical and materials science avenues for selecting a proper combination of water and organic solvents for an emulsion that allows an efficient two-phase separation of viral particles. The project may result in a new technology for early (presymptomatic) detection of the live virus, which offers the possibility of providing at the site-of-need a pre-screening test for prevention of further viral outbreaks and spread of the disease.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

严重急性呼吸综合症冠状病毒（SARS-COV-2）的快速爆发是前所未有的公共卫生紧急情况，需要立即注意以降低发病率和死亡率。在新型的电晕病毒（Covid-19）暴发期间，似乎成千上万的潜在感染的人没有明显的症状，在传播全球大流行病中发挥了作用，在美国，感染水平很高。解决此问题需要开发用于病毒测试的新技术。重要的是，至关重要的是，对于大量受感染的个体（包括没有明显症状的人），具有可用的简单，可靠和具有成本效益的方法，以便早日检测病毒。此外，预计这种新方法可以评估疾病暴发条件下的大量测试样本，并且是理解免疫水平的关键。有了这个奖项，化学划分的化学测量和成像计划正在支持DRS的研究。 Slava V. Rotkin，Daniel J. Hayes，Suresh V. Kuchipudi（宾夕法尼亚州立大学，PSU）和Tetyana Ignatova博士（北卡罗来纳大学格林斯伯勒大学，UNCG）及其合作者及其合作者开发了一种小说，准确，准确的，廉价的预先挑战的现场挑战，以对现场挑战进行了挑战，以构成巨大的挑战。新的敏感性途径解决了对疾病早期病毒检测的重要问题，而其他方法的测试结果却不那么明显，这些方法限制了明显的流行病学形象的创造。该项目研究了一种新的化学方法，该方法可以通过使用施加到纳米颗粒的磁力组合来“看到”浓缩的活病毒颗粒，这些磁力在创建微型液体下降过程中与病毒及其周围环境之间结合的纳米颗粒，所有这些都发生在3-D打印的传感器设备内。新的传感器具有巨大的潜力，可以提供快速，容易，在需要的地方，有关病毒存在的信息及其在病毒脱落机制和防止疾病传播方面的作用。在人类和动物中，这项技术可用于检测其他重要的基于病毒的疾病。该项目旨在开发一种新技术进行个人护理的快病毒测试 - 响应但不限于Covid-19。具体而言，该项目致力于检测少于1,000个病毒颗粒的病毒剂量，该病毒剂量与感染个体的呼吸样本中的典型水平相对应，此前可以感知严重的症状。由于与分析物化学反应的基本限制，因此达到非核酸方法的检测极低是一项挑战任务。在该项目中，通过将荧光标记的磁性纳米颗粒与SARS-COV-2 Corona的糖蛋白结合结合，然后进行荧光标记的磁性纳米颗粒的选择性结合，然后进行额外的分析物浓度。该项目旨在回答有关：通过血管紧张素转化酶2标记染色标签和纳米颗粒的血管紧张素的病毒表面识别活病毒的基本问题；这种“三明治”组装加速的化学和物理过程在乳液中瞬时液滴的微体积中；以及化学和材料科学的途径，用于选择适当的水和有机溶液的乳液，从而有效地将病毒颗粒分离。 The project may result in a new technology for early (presymptomatic) detection of the live virus, which offers the possibility of providing at the site-of-need a pre-screening test for prevention of further viral outbreaks and spread of the disease.This award reflects NSF's statutory mission and has been deemed precious of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.